Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 6, 2009 - Issue 3
Submit an article Journal homepage
546
Views
74
CrossRef citations to date
0
Altmetric
Review

Chitosan nanoparticles for drug delivery to the eye

Patrizia Paolicelli Professor, Faculty of Pharmacy University of Santiago de Compostela Department of Pharmacy and Pharmaceutical Technology Campus Sur 15782, Santiago de Compostela, Spain +34 981 563100; +34 981 547148; [email protected]
,
Maria de la Fuente Professor, Faculty of Pharmacy University of Santiago de Compostela Department of Pharmacy and Pharmaceutical Technology Campus Sur 15782, Santiago de Compostela, Spain +34 981 563100; +34 981 547148; [email protected]
,
Alejandro Sánchez Professor, Faculty of Pharmacy University of Santiago de Compostela Department of Pharmacy and Pharmaceutical Technology Campus Sur 15782, Santiago de Compostela, Spain +34 981 563100; +34 981 547148; [email protected]
,
Begoña Seijo Professor, Faculty of Pharmacy University of Santiago de Compostela Department of Pharmacy and Pharmaceutical Technology Campus Sur 15782, Santiago de Compostela, Spain +34 981 563100; +34 981 547148; [email protected]
&
María José Alonso Professor, Faculty of Pharmacy University of Santiago de Compostela Department of Pharmacy and Pharmaceutical Technology Campus Sur 15782, Santiago de Compostela, Spain +34 981 563100; +34 981 547148; [email protected]
Pages 239-253 | Published online: 16 Mar 2009

Bibliography

  • Baeyens R, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 1997;72:191-202
  • Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Deliv Rev 1995;16:39-43
  • Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995;16:3-19
  • Schoenwald RD. Ocular drug delivery: pharmacokinetic considerations. Clin Pharmacokinet 1990;18:255-69
  • Sasaki H, Yamamura K, Mukai T, et al. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 1999;16:85-146
  • Edwards A, Prausnitz MR. Predicted permeability of the cornea to topical drugs. Pharm Res 2001;18:1497-508
  • Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 2006;58:1136-63
  • Hornof M, Toropainen E, Urtti A. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 2005;60:207-25
  • Mindel J, Smith H, Jacobs M, et al. Drug reservoirs in topical therapy. Invest Ophthalmol Vis Sci 1984;25:346-50
  • Avtar R, Tandon D. Modeling the drug transport in the anterior segment of the eye. Eur J Pharm Sci 2008;35:175-82
  • Imran A. The noncorneal route in ocular drug delivery. Drugs Pharm Sci 2003;130:335-63
  • Hosoya KI, Lee VHL, Kim KJ. Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanism and their regulation. Eur J Pharm Biopharm 2005;60:227-40
  • Cordeiro MF, Schultz GS, Ali RR, et al. Molecular therapy in ocular wound healing. Br J Ophthalmol 1999;83:1219-24
  • Hauswirth W, Beaufrere L. Ocular gene therapy: Quo Vadis? Invest Ophthalmol Vis Sci 2000;41:2821-26
  • Bouk N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002;8:330-34
  • Fattal E, Bochot A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Del Rev 2006;58:1203-23
  • Bloquel C, Bourges JB, Touchard E, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Del Rev 2006;58:1224-42
  • Harbour JM, Worley L, Ma D, Cohen M. Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch Ophthalmol 2002;120:1341-46
  • Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131-35
  • Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008;13:135-43
  • Le Bourlais CA, Acar L, Zia H, et al. Ophthalmic drug delivery systems – recent advances. Prog Retin Eye Res 1998;17(1):33-58
  • Mainardes R, Urban M, Cinto P, et al. Colloidal carriers in ophthalmic drug delivery. Curr Drug Targets 2005;6:363-71
  • Sultana Y, Aqil M, Ali A, Samad A. Advances in the topical ocular drug delivery. Expert Rev Ophthalmol 2007;2:309-23
  • Calvo P, Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J Pharm Sci 1996;85:530-36
  • Fronza T, Campos A, Teixeira H. Nanoemulsions as delivery systems for ophthalmic drugs. Acta Farm Bonaerense 2004;23:558-66
  • Losa C, Marchal-Heussler L, Orallo F, et al. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993;10:80-87
  • Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Development of positively charged colloidal drug carriers: chitosan-coated polyester nanocapsules and submicron-emulsions. Colloid Polym Sci 1997;275:46-53
  • Sánchez A, Alonso MJ. Nanoparticular carriers for ocular drug delivery. Nanoparticulates as drug carriers. Imperial College Press, London, UK: VP Torchilin; 2006. p. 649-73
  • Vanderwoot J, Ludwig A. Ocular drug delivery: nanomedicine applications. Nanomedicine 2007;2:11-21
  • Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008;13:144-51
  • Wood RW, Lee HK, Kreuter J, Robinson JR. Ocular disposition of poly-hexyl-2-cyano (3-14C)acrylate nanoparticles in the albino rabbit. Int J Pharm 1985;23:175-83
  • Langer K, Zimmer A, Kreuter J. Acrylic nanoparticles for ocular drug delivery. STP Pharm Sci 1997;7:445-51
  • Calvo P, Thomas C, Alonso MJ, et al. Study of the mechanism of interaction of poly-ϵ-caprolactone nanocapsules with the cornea by confocal laser scanning microscopy. Int J Pharm 1994;103:283-91
  • De Campos A, Sánchez A, Gref R, et al. The effect of a PEG vs a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sci 2003;20:73-81
  • Florence AT, Hussain N. Transcytosis of nanoparticles and dendrimer delivery systems: evolving vistas. Adv Drug Del Rev 2001;50:S69-89
  • Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indometacin by novel ocular drug carriers. J Pharm Pharmacol 1996;48:1147-52
  • Bucolo C, Maltese A, Drago F. When nanotechnology meets the ocular surface. Expert Rev Ophthalmol 2008;3:325-32
  • Barbu E, Verestiuc L, Nevell TG, Tsibouklis J. Polymeric materials for ophthalmic drug delivery: trends and perspectivas. J Mater Chem 2006;16:3439-43
  • Takeuchi H, Yamamoto H, Niwa T, et al. Enteral absorption of insulina in rats from mucoadhesive chitosan-coated liposomes. Pharm Res 1996;13:896-901
  • Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Del Rev 2001;47:39-54
  • Vila A, Sánchez A, Tobio M, et al. Design of biodegradable nanoparticles for protein delivery. J Control Release 2002;78:15-24
  • Prego C, Garcia M, Torres L, Alonso MJ. Transmucosal macromolecular drug delivery. J Control Release 2005;101:151-62
  • Donalson K, Seaton A. The Janus faces of nanoparticles. J Nanosci Nanotechnol 2007;7:4607-11
  • Tetley TD. Health effects of nanomaterials. Biochem Soc Trans 2007;35:527-31
  • Sogias IA, Williams AC, Khuoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules 2008;9:1837-42
  • Pangburn SH, Trescony PV, Heller J. Lysozyme degradation of partially deacetylated chitin, its films and hydrogels. Biomaterials 1982;3:105-108
  • Hirano S, Seino H, Akiyama Y, Nonaka I. Biocompatibility of chitosan by oral and intravenous administration. Polym Eng Sci 1989;59:897-901
  • Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994;11:1358-61
  • Schipper NGM, Olsson S, Hoostraate AJ, et al. Chitosan as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res 1997;14:923-29
  • Koch MA, Dodane V, Khan MA, Merwin JR. Chitosan induced effects on epithelial morphology as seen by confocal scanning microscopy. Scanning 1998;20:262-63
  • Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm 1999;182:21-32
  • Mitra S, Gaur U, Ghosh PC, Maitra AN. Tumour targeted delivery of encapsulated dextran–doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001;74:317-23
  • De Campos A, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the ocular retention of drugs. Application to cyclosporin A. Int J Pharm 2001;224:159-68
  • De Campos A, Diebold Y, Carvalho ELS, et al. In: De Campos A, editor, Evaluación biofarmacéutica de sistemas coloidales para el transporte de medicamentos por vía ocular. Doctoral Thesis, 2002. p. 48-76
  • Köping-Höggård M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure–property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 2001;8:1108-21
  • Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145-50
  • Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006;14:476-84
  • Rojanarata T, Opanasopit P, Techaarpornkul S, et al. Chitosan–thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res 2008: published online 18 June 2008, published online 18 June 2008, doi:10.1007/s11095-008-9648-6
  • Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res 2008;48:319-24
  • Short BG. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations. Toxicol Pathol 2008;36:49-62
  • Walker S, Sofia MJ, Kakarla R, et al. Cationic facial amphiphiles: a promising class of transfection agents. Proc Natl Acad Sci USA 1996;93:1585-90
  • Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan–polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997;63:125-32
  • Janes KA, Alonso MJ. Depolymerized chitosan nanoparticles for protein delivery: preparation and characterization. J Appl Polym Sci 2003;88:2769-76
  • Richardson SCW, Kolbe HVJ, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 1999;178:231-43
  • Schipper NGM, Varum KM, Artursson P. Chitosan as absorption enhancers for poorly absorbable drugs1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelia (Caco-29 dells). Pharm Res 1996;13:1686-92
  • Henriksen I, Green KL, Smart JD, et al. Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm 1996;145:231-40
  • Janes KA, Fresneau MP, Marazuela A, et al. Chitosan nanoparticles as delivery systems for doxorubicin. J Control Release 2001;73:255-67
  • Gang Q, Wang T. Chitosan nanoparticles as protein delivery carrier – systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 2007;59(1):24-34
  • Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006;115(2):216-25
  • Csaba N, Köping-Höggård M, Fernandez-Megia E, et al. Ionically crosslinked chitosan nanoparticles as gene delivery systems: effect of PEGylation degree on in vitro and in vivo gene transfer. J Biomed Nanosci (accepted for publication)
  • Zimmer A, Kreuter J, Robinson JK. Studies on the transport pathway of PBCA nanoparticles in ocular tissues. J Microencapsul 1991;8:497-504
  • Enríquez de Salamanca A, Diebold Y, Calonge M, et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006;47:1416-25
  • Hirano S, Tsuchida H, Nagao N. N-acetylation in chitosan and the rate of its enzymic hydrolysis. Biomaterials 1989;10:574-76
  • Aiba SI. Studies on chitosan: relationship between Nacetyl group distribution pattern and chitinase digestibility of partially N-acetylated chitosans. Int J Biol Macromol 1993;15:241-45
  • Rohen JW, Lutjen-Drecoll E. Functional morphology of the conjunctiva. In: Lemp MA, Marquard R, editors, The dry eye: a comprehensive guide. Springer-Verlag. Berlin, 1992. p. 35-63
  • Ren D, Yi H, Wang W, Ma X. The enzymatic degradation and swelling properties of chitosan matrices with different degrees of N-acetylation. Carbohydr Res 2005;340:2403-10
  • Knapczyk J, Krowczynski L, Krzck J, et al. Requirements of chitosan for pharmaceutical and biomedical applications. In: Skak-Braek G, Anthonsen T, Sandford P, editors, Chitin and chitosan: sources, chemistry, biochemistry, physical properties and applications. Elsevier, London, 1989. p. 657-63
  • Aspden TJ, Mason JDT, Jones NS, et al. Chitosan as a nasal delivery system: the effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997;86:509-13
  • De Campos AM, Diebold Y, Carvalho EL, et al. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004;21:803-10
  • Griffith JF, Nixon GA, Bruce RD, et al. Dose-response studies with chemical irritants in the albino rabbit eye as a basis for selecting optimum testing conditions for predicting hazard to the human eye. Toxicol Appl Pharmacol 1980;55:501-13
  • Prow TW, Bhutto I, Kim SY, et al. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium. Nanomedicine: Nanotechnology, Biology, Medicine 2008;4:340-49
  • Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 2005;57:1555-63
  • Calvo P, Vila-Jato JL, Alonso MJ. Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. Int J Pharm 1997;153:41-50
  • Jain AK, Chalasani KB, Khar RK, et al. Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery. J Drug Target 2007;15:417-27
  • Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005;290:155-59
  • Yuan XB, Yuan YB, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm 2008;349:241-48
  • Marchal-Heussler L, Fessi H, Devissaguet JP, et al. Colloidal drug delivery systems for the eye. A comparison of the efficacy of three different polymers: polyisobutylcyanoacrylate, polylactic-co-glycolic acid, and poly-epsilon-caprolacton. STP Pharma Sci 1992;2(1):98-104
  • Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 1997;63:125-32
  • Kao HJ, Lin HR, Lo YL, Yu SP. Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol 2006;58:179-86
  • Lin HR, Yu SP, Kuo CJ, et al. Pilocarpine-loaded chitosan-PAA nanosuspension for ophthalmic delivery. J Biomater Sci Polym Ed 2007;18:205-21
  • Motwani SK, Chopra S, Talegaonkar S, et al. Chitosan–sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008;68:513-25
  • Liu Z, Li J, Nie S, et al. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 2006;315:12-17
  • Lin HR, Sung KC, Vong WJ. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine. Biomacromolecules 2004;5:2358-65
  • Liu W, Griffith M, Li F. Alginate microsphere-collagen composite hydrogel for ocular drug delivery and implantation. J Mater Sci Mater Med 2008;19:3365-71
  • Gilhotra RM, Mishra DN. Alginate-chitosan film for ocular drug delivery: effect of surface cross-linking on film properties and characterization. Pharmazie 2008;63:576-79
  • Goycoolea F, Lollo G, Alonso MJ. Chitosan-alginate nanoparticles for nasal administration of insulin in rabbits. Proceedings of 1st conference on innovation in drug delivery: from biomaterials to devices. Naples, Italy, 30 September–3 October 2007
  • Sarmento B, Ribeiro A, Veiga F, et al. Oral Bioavailability of insulina contained in polysaccharidic nanoparticles. Biomacromolecules 2007;8:3054-60
  • de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronan based nanocarriers for transmucosal delivery of macromolecules. Macromol Biosci 2008;8:441-50
  • Lapcik L Jr, Lapcik L, De Smedt S, et al. Hyaluronan: preparation, structure, properties and applications. Chem Rev 1998;98:2663-83
  • Cobo M, Beaty N. VITRAX (sodium hyaluronate) in anterior segment surgery: a review and clinical study summary. Adv Ther 1990;7:51-60
  • Goa KL, Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 1994;47:536-66
  • Prestwich GD, Kuo JW. Chemically-modified HA for therapy and regenerative medicine. Curr Pharm Biotechnol 2008;9:242-45
  • Balazs EA. Hyaluronan as an ophthalmic viscoelastic device. Curr Pharm Biotechnol 2008;9:236-38
  • Lerner LE, Schwartz DM, Hwang DG, et al. Hyaluronan and CD44 in the human cornea and conjunctiva. Exp Eye Res 1998;67:481-84
  • Fagerholm P. Endogenous hyaluronan in the anterior segment of the eye. Prog Reti Eye Res 1996;15:281-96
  • Aragona P. Hyaluronan in the treatment of ocular surface disorders. Chemistry and biology of Hyaluronan. Elsevier Ltd, Oxford, UK: HG Garga, CA Hales; 2004. p. 529-51
  • Greaves JL, Wilson CG. Treatment of diseases of the eye with mucoadhesive delivery systems. Adv Drug Del Rev 1993;11:349-83
  • Kyyronen K, Hume L, Urtti A, et al. Methylprednisolone esters of hyaluronic acid in ophthalmic drug delivery: in vitro and in vivo release studies. Int J Pharm 1992;80:161-69
  • Barbault-Foucher S, Gref R, Russo P, Bochot A. Design of Poly-ϵ-caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J Control Release 2002;83:365-75
  • Yerushalmi N, Margalit R. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys 1998;349:21-6
  • Hornof M, de la Fuente M, Hallikanen M, et al. Low molecular weight hyaluronan shielding of DNA/PEI polyplexes facilitates CD44 receptor mediated uptake in human corneal epithelial cells. J Gene Med 2008;10:70-80
  • de la Fuente M, Seijo B, Alonso MJ. Design of novel polysaccharidic nanostructures for gene delivery. Nanotechnology 2008;19:1-9
  • Köping-Höggåard M, Vårum KM, Issa M, et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004;11:1441-52
  • Almond A. Hyaluronan. Cell Mol Life Sci 2007;64:1591-96
  • Menzel EJ, Farr C. Hyaluronidase and its substrate hyaluronate: biochemistry, biological activities and therapeutic uses. Cancer Lett 1998;131:3-11
  • Ito T, Iida-Tanaka N, Niiidome T, et al. Hyaluronic acid and its derivative as a multi-functional gene expression enhancer: Protection from non-specific interactions, adhesion to targeted cells, and transcriptional activation. J Control Release 2006;112:382-88
  • Ruponen M, Rönkko S, Honkakoski P, et al. Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes. J Biol Chem 2001;276:33875-80
  • de la Fuente M, Seijo B, Alonso MJ. Novel hyaluronic acid/chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008;49:2016-24
  • Eliaz RE, Szoka FC Jr. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001;61(6):2592-601
  • de la Fuente M, Seijo B, Alonso MJ. Bioadhesive hyaluronan/chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008;15:668-76
  • Contreras-Ruiz L, de la Fuente M, García-Vázquez C, et al. Improved in vivo tolerance of hyaluronic acid chitosan nanoparticles. (Submitted)
  • Viso E, Rodriguez-Ares MT, Gude F. Prevalence of and associated factors for dry eye in a Spanish adult population (The Salnes Eye Study). Ophtalm Ep 2008 In press
  • Ramamoorthy P, Sinnott LT, Nichols JJ. Treatment, material, care, and patient-related factors in contact lens-related dry eye. Optom Vis Sci 2008;85:764-72
  • Peeters L, Sanders NN, Demeester J, De Smedt SC. Challenges in non-viral ocular gene transfer. Biochem Soc Trans 2007;35:47-49
  • Farjo R, Skaggs J, Quiambao AB, et al. Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 2006;20:1-8
  • Bloquel C, Bourges JL, Touchard E, et al. Non-viral ocular gene therapy: potential ocular therapeutic avenues. Adv Drug Deliv Rev 2006;58:1224-42
  • Belting M, Sandgren S, Wiittrup A. Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev 2005;57:505-27
  • Lehn P, Fabrega S, Oudrhiri N, Navarro J. Gene delivery systems: bridging the gap between recombinant viruses and artificial vectors. Adv Drug Deliv Rev 1998;30:5-11
  • Lollo CP, Banaszczyk MG, Chiou HC. Obstacles and advances in non-viral gene delivery. Curr Opin Mol Ther 2000;2:136-42
  • Labhasetwar V. Nanotechnology for drug and gene therapy: the importance of understanding molecular mechanism of delivery. Curr Opin Biotechnol 2005;16:674-80
  • Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007;28:1553-64
  • Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-60
  • Yuan X, Li H, Yuan Y. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym 2006;65:337-45
  • Qu X, Khutoryanskiy VV, Stewart A, et al. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. Biomacromolecules 2006;7:3452-59

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.